Acipimox
Acipimox is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target hydroxycarboxylic acid receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 2 | 1 | — | 3 | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 2 | 2 | — | 2 | 5 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | 1 | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | 1 | — | — | 4 | 5 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | — | — | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 1 | 2 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | — | 1 | — | — | 1 | 2 |
| Abdominal obesity | D056128 | — | — | — | 1 | — | — | — | 1 |
| Bulimia | D002032 | — | F50.2 | — | 1 | — | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | — | — | — | 1 |
| Bulimia nervosa | D052018 | EFO_0005204 | F50.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 2 | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 2 | 2 |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 2 | 2 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 1 | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
| Brain diseases | D001927 | — | G93.40 | — | — | — | — | 1 | 1 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | — | — | 1 | 1 |
| Metabolism | D008660 | GO_0008152 | — | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Acipimox |
| INN | acipimox |
| Description | 5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cnc(C(=O)O)c[n+]1[O-] |
Identifiers
| PDB | — |
| CAS-ID | 51037-30-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL345714 |
| ChEBI ID | — |
| PubChem CID | 5310993 |
| DrugBank | — |
| UNII ID | K9AY9IR2SD (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HCAR2
HCAR2
Organism
Homo sapiens
Gene name
HCAR2
Gene synonyms
GPR109A, HCA2, HM74A, NIACR1
NCBI Gene ID
Protein name
hydroxycarboxylic acid receptor 2
Protein synonyms
G protein-coupled receptor HM74a, G-protein coupled receptor 109A, G-protein coupled receptor HM74A, hydroxy-carboxylic acid receptor 2, Niacin receptor 1, Nicotinic acid receptor
Uniprot ID
Mouse ortholog
Hcar2 (80885)
hydroxycarboxylic acid receptor 2 (Q9EP66)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 890 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
145 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use